UNSPSC 51182418: Calcium acetate

This classification denotes a nutritional supplement, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y882YXF34X. European Medicines Agency schedules Calcium acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13160MIG. Calcium acetate generally arises in the molecular formula C4H6CAO4. The term CALCIUM ACETATE is a United States Homeopathic Pharmacopoeia Name designation. Most nations schedule calcium acetate under HS 29152900 and SITC 51371.

As of Q4 2014, CALCIUM ACETATE remains the US FDA Preferred Term for this commodity. Calcium acetate bears US NLM identifiers UMLS ID C0717537 and NCI Concept Code C47429. SMILES: CC(=O)[O-].CC(=O)[O-].[Ca+2].

UNSPSC 51182418 Calcium acetate is a Commodity code that captures pharmaceutical active ingredients and finished drugs state and local governments procure for institutional use, including correctional facilities, health benefit programs, and multistate cooperative purchasing alliances. Recent solicitations show state and local demand for generic pharmaceuticals, over-the-counter products, and specialty medications including those used in drug testing, correctional health services, and state employee health plans. The code reflects purchasing across institutional pharmacy benefit administration, laboratory testing support, and direct pharmaceutical supply arrangements negotiated outside traditional pharmacy benefit manager networks.

State and local buyers under this code include correctional departments, state health and human services agencies, and multistate cooperative purchasing alliances serving participating jurisdictions. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with approximately 25,000 annual tests across immunoassay and confirmation methodologies (response due July 23, 2026; contract value $600,000 over two years plus optional renewals). The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon (proposals due March 26, 2026; two-year contract term with optional extensions). Activity concentrates in Texas and Minnesota, with MMCAP's multistate reach extending cooperative purchasing to participating jurisdictions beyond Minnesota's borders.